## Jin Zhu

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9064482/publications.pdf

Version: 2024-02-01

51	1,006	17 h-index	29
papers	citations		g-index
53	53	53	1609
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	The novel therapeutic strategy of vilazodone-donepezil chimeras as potent triple-target ligands for the potential treatment of Alzheimer's disease with comorbid depression. European Journal of Medicinal Chemistry, 2022, 229, 114045.	2.6	5
2	Drug Repurposing of Quisinostat to Discover Novel <i>Plasmodium falciparum</i> HDAC1 Inhibitors with Enhanced Triple-Stage Antimalarial Activity and Improved Safety. Journal of Medicinal Chemistry, 2022, 65, 4156-4181.	2.9	9
3	Discovery of novel dual RAGE/SERT inhibitors for the potential treatment of the comorbidity of Alzheimer's disease and depression. European Journal of Medicinal Chemistry, 2022, 236, 114347.	2.6	7
4	Novel niclosamide-derived adjuvants elevating the efficacy of polymyxin B against MDR Pseudomonas aeruginosa DK2. European Journal of Medicinal Chemistry, 2022, 236, 114318.	2.6	3
5	Design and synthesis of novel hydroxamic acid derivatives based on quisinostat as promising antimalarial agents with improved safety. , 2022, $1,\dots$		O
6	Cucurbitacin B-induced G2/M cell cycle arrest of conjunctival melanoma cells mediated by GRP78–FOXM1–KIF20A pathway. Acta Pharmaceutica Sinica B, 2022, 12, 3861-3876.	5.7	11
7	Development of novel benzimidazole-derived neddylation inhibitors for suppressing tumor growth in vitro and in vivo. European Journal of Medicinal Chemistry, 2021, 210, 112964.	2.6	11
8	Discovery of Novel <i>Plasmodium falciparum</i> HDAC1 Inhibitors with Dual-Stage Antimalarial Potency and Improved Safety Based on the Clinical Anticancer Drug Candidate Quisinostat. Journal of Medicinal Chemistry, 2021, 64, 2254-2271.	2.9	21
9	Fangchinoline suppresses conjunctival melanoma by directly binding FUBP2 and inhibiting the homologous recombination pathway. Cell Death and Disease, 2021, 12, 380.	2.7	9
10	Repurposing of antitumor drug candidate Quisinostat lead to novel spirocyclic antimalarial agents. Chinese Chemical Letters, 2021, 32, 1660-1664.	4.8	8
11	Antiaging Effects of Vicatia thibetica de Boiss Root Extract on Caenorhabditis elegans and Doxorubicin-Induced Premature Aging in Adult Mice. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-13.	1.9	1
12	Discovery of synergistic activity of fluoroquinolones in combination with antimicrobial peptides against clinical polymyxin-resistant Pseudomonas aeruginosa DK2. Chinese Chemical Letters, 2020, 31, 413-417.	4.8	8
13	Discovery of nitazoxanide-based derivatives asÂautophagy activators for the treatment ofÂAlzheimer's disease. Acta Pharmaceutica Sinica B, 2020, 10, 646-666.	5.7	18
14	Targeting virulence factors as an antimicrobial approach: Pigment inhibitors. Medicinal Research Reviews, 2020, 40, 293-338.	5.0	18
15	Development of disulfide-derived fructose-1,6-bisphosphatase (FBPase) covalent inhibitors for the treatment of type 2 diabetes. European Journal of Medicinal Chemistry, 2020, 203, 112500.	2.6	8
16	A novel multistage antiplasmodial inhibitor targeting Plasmodium falciparum histone deacetylase 1. Cell Discovery, 2020, 6, 93.	3.1	23
17	Repurposing of antipsychotics perphenazine for the treatment of endometrial cancer. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127239.	1.0	9
18	Rational Design of Novel Selective Dual-Target Inhibitors of Acetylcholinesterase and Monoamine Oxidase B as Potential Anti-Alzheimer's Disease Agents. ACS Chemical Neuroscience, 2019, 10, 482-496.	1.7	28

#	Article	IF	CITATIONS
19	Nitazoxanide, an anti-parasitic drug, efficiently ameliorates learning and memory impairments in AD model mice. Acta Pharmacologica Sinica, 2019, 40, 1279-1291.	2.8	27
20	Novel Staphyloxanthin Inhibitors with Improved Potency against Multidrug Resistant <i>Staphylococcus aureus</i> . ACS Medicinal Chemistry Letters, 2018, 9, 233-237.	1.3	8
21	Design, synthesis and evaluation of vilazodone-tacrine hybrids as multitarget-directed ligands against depression with cognitive impairment. Bioorganic and Medicinal Chemistry, 2018, 26, 3117-3125.	1.4	19
22	Discovery of Potent Benzocycloalkane Derived Diapophytoene Desaturase Inhibitors with an Enhanced Safety Profile for the Treatment of MRSA, VISA, and LRSA Infections. ACS Infectious Diseases, 2018, 4, 208-217.	1.8	4
23	Discovery of novel piperonyl derivatives as diapophytoene desaturase inhibitors for the treatment of methicillin-, vancomycin- and linezolid-resistant Staphylococcus aureus infections. European Journal of Medicinal Chemistry, 2018, 145, 235-251.	2.6	12
24	Discovery of novel propargylamine-modified 4-aminoalkyl imidazole substituted pyrimidinylthiourea derivatives as multifunctional agents for the treatment of Alzheimer's disease. European Journal of Medicinal Chemistry, 2018, 143, 33-47.	2.6	60
25	Novel Terminal Bipheny-Based Diapophytoene Desaturases (CrtN) Inhibitors as Anti-MRSA/VISR/LRSA Agents with Reduced hERG Activity. Journal of Medicinal Chemistry, 2018, 61, 224-250.	2.9	22
26	Discovery of novel purine nucleoside derivatives as phosphodiesterase 2 (PDE2) inhibitors: Structure-based virtual screening, optimization and biological evaluation. Bioorganic and Medicinal Chemistry, 2018, 26, 119-133.	1.4	11
27	Discovery of novel Syk/PDGFR-î±/c-Kit inhibitors as multi-targeting drugs to treat rheumatoid arthritis. Bioorganic and Medicinal Chemistry, 2018, 26, 4375-4381.	1.4	8
28	Development of the First Generation of Disulfide-Based Subtype-Selective and Potent Covalent Pyruvate Dehydrogenase Kinase 1 (PDK1) Inhibitors. Journal of Medicinal Chemistry, 2017, 60, 2227-2244.	2.9	55
29	Discovery of Potent, Selective Stem Cell Factor Receptor/Platelet Derived Growth Factor Receptor Alpha (c-KIT/PDGFRα) Dual Inhibitor for the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs). Journal of Medicinal Chemistry, 2017, 60, 5099-5119.	2.9	13
30	Discovery of new antimalarial agents: Second-generation dual inhibitors against FP-2 and PfDHFR via fragments assembely. Bioorganic and Medicinal Chemistry, 2017, 25, 6467-6478.	1.4	12
31	Novel Inhibitors of Staphyloxanthin Virulence Factor in Comparison with Linezolid and Vancomycin versus Methicillin-Resistant, Linezolid-Resistant, and Vancomycin-Intermediate <i>Staphylococcus aureus</i> Infections in Vivo. Journal of Medicinal Chemistry, 2017, 60, 8145-8159.	2.9	21
32	Novel Vilazodone–Tacrine Hybrids as Potential Multitarget-Directed Ligands for the Treatment of Alzheimer's Disease Accompanied with Depression: Design, Synthesis, and Biological Evaluation. ACS Chemical Neuroscience, 2017, 8, 2708-2721.	1.7	32
33	Discovery of Benzocycloalkane Derivatives Efficiently Blocking Bacterial Virulence for the Treatment of Methicillin-Resistant <i>S. aureus</i> (MRSA) Infections by Targeting Diapophytoene Desaturase (CrtN). Journal of Medicinal Chemistry, 2016, 59, 4831-4848.	2.9	23
34	2-Arylbenzo[ <i>b</i> ) furan derivatives as potent human lipoxygenase inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2016, 31, 98-105.	2.5	13
35	Development of Multifunctional Pyrimidinylthiourea Derivatives as Potential Anti-Alzheimer Agents. Journal of Medicinal Chemistry, 2016, 59, 8326-8344.	2.9	69
36	Bufexamac ameliorates LPS-induced acute lung injury in mice by targeting LTA4H. Scientific Reports, 2016, 6, 25298.	1.6	19

#	Article	IF	CITATIONS
37	Discovery of Potent Benzofuran-Derived Diapophytoene Desaturase (CrtN) Inhibitors with Enhanced Oral Bioavailability for the Treatment of Methicillin-Resistant <i>Staphylococcus aureus</i> Infections. Journal of Medicinal Chemistry, 2016, 59, 3215-3230.	2.9	40
38	Discovery of Benzylidene Derivatives as Potent Syk Inhibitors: Synthesis, SAR Analysis, and Biological Evaluation. Archiv Der Pharmazie, 2015, 348, 463-474.	2.1	4
39	Design, Synthesis, and Biological Evaluation of Novel Nonsteroidal Farnesoidâ€X Receptor (FXR) Antagonists: Molecular Basis of FXR Antagonism. ChemMedChem, 2015, 10, 1184-1199.	1.6	16
40	Discovery of Novel Small Molecule Anti-HCV Agents via the CypA Inhibitory Mechanism Using O-Acylation-Directed Lead Optimization. Molecules, 2015, 20, 10342-10359.	1.7	16
41	Identification, synthesis and pharmacological evaluation of novel anti-EV71 agents via cyclophilin A inhibition. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 5682-5686.	1.0	11
42	Discovery of New Imidazole Derivatives Containing the 2,4-Dienone Motif with Broad-Spectrum Antifungal and Antibacterial Activity. Molecules, 2014, 19, 15653-15672.	1.7	23
43	Synthesis of î³â€Oxoâ€Î±,βâ€dehydroâ€Î±â€amino Acids from <i>N</i> àê€' <i>tert</i> àê€Butyloxycarbonylâ€Î±â€kr Carbonylmethyl 2â€Pyridinylsulfones via an Mannichâ€Elimination Cascade. Asian Journal of Organic Chemistry, 2014, 3, 766-768.	nino Ester 1.3	rs and 2
44	Organocatalytic Enantioselective Friedel–Crafts Reaction of 1â€Naphthols with Isatins and an Unexpected Spontaneous Dehydration Process. Asian Journal of Organic Chemistry, 2014, 3, 480-486.	1.3	20
45	Design and synthesis of small molecular dual inhibitor of falcipain-2 and dihydrofolate reductase as antimalarial agent. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 958-962.	1.0	37
46	Efficient preparation of trans- $\hat{l}$ ±, $\hat{l}$ 2-unsaturated aldehydes from saturated aldehydes by oxidative enamine catalysis. Science China Chemistry, 2011, 54, 1932-1936.	4.2	8
47	2-Amido-3-(1H-Indol-3-yl)-N-Substitued-Propanamides as a New Class of Falcipain-2 Inhibitors. 1. Design, Synthesis, Biological Evaluation and Binding Model Studies. Molecules, 2009, 14, 494-508.	1.7	10
48	A Direct Amineâ€Palladium Acetate Cocatalyzed Saegusa Oxidation Reaction of Unmodified Aldehydes to α,βâ€Unsaturated Aldehydes. Advanced Synthesis and Catalysis, 2009, 351, 1229-1232.	2.1	88
49	Refinement and 3Dâ€QSAR Studies of Inhibitors of Cyclophilin A Containing Amide Linker. QSAR and Combinatorial Science, 2009, 28, 183-193.	1.5	4
50	Discovering Potent Small Molecule Inhibitors of Cyclophilin A Using de Novo Drug Design Approach. Journal of Medicinal Chemistry, 2009, 52, 5295-5298.	2.9	92
51	2-(3,4-Dihydro-4-Oxothieno[2,3-d]pyrimidin-2-ylthio) Acetamides as a New Class of Falcipain-2 Inhibitors. 3. Design, Synthesis and Biological Evaluation. Molecules, 2009, 14, 785-797.	1.7	10